Progress in type II dehydroquinase inhibitors: from concept to practice

Area of Science:

• Microbiology
• Drug Discovery
• Structural Biology

Background:

• Antibiotic resistance is a growing global health concern, diminishing the efficacy of current treatments for diseases like malaria, tuberculosis, and pneumonia.
• The shikimic acid pathway, present in some parasites and bacteria, is a potential target for novel antimicrobial agents.
• Opportunistic infections in immunocompromised individuals, such as HIV patients, necessitate the development of new therapeutic strategies.

Purpose of the Study:

• To review recent advancements in the development of inhibitors targeting the type II dehydroquinase enzyme within the shikimic acid pathway.
• To explore the utility of X-ray crystal structures in understanding enzyme-inhibitor interactions and guiding drug design.

Main Methods:

• Analysis of X-ray crystal structures of dehydroquinase enzymes complexed with inhibitors.
• Investigation of key interactions at the enzyme's active site.
• Discussion of structure-based drug design principles for potent and selective inhibitors.

Main Results:

• Recent X-ray crystal structures of dehydroquinases from *Streptomyces coelicolor* and *Mycobacterium tuberculosis* with bound inhibitors have been solved.
• These structures reveal critical interactions governing inhibitor binding.
• Insights into the catalytic mechanism of type II dehydroquinase have been elucidated.

Conclusions:

• X-ray crystallography of dehydroquinase-inhibitor complexes is a valuable tool for understanding enzyme function.
• This structural information aids in the rational design of potent and selective enzyme inhibitors.
• Targeting the shikimic acid pathway presents a viable approach for developing new antibiotics against resistant pathogens and opportunistic infections.